Advertisement
CVS vs ELV
Which Stock Would AI Choose? CVS Health (CVS) vs. Elevance Health (ELV) Stock Comparison
Key Takeaways
- CVS Health reported stronger year-over-year revenue growth in its most recent quarter compared to Elevance Health, with a 6.2% increase versus 1.5%.
- CVS stock has delivered superior recent performance, rising approximately 7.5% over the past month and showing YTD returns near 34%, outpacing ELV's more modest gains.
- Both companies raised full-year 2026 earnings guidance following first-quarter results, signaling underlying business resilience in the healthcare sector.
- CVS benefits from diversified exposure across retail pharmacy, pharmacy benefit management, and insurance, while ELV focuses primarily on managed care and government programs.
- Analyst sentiment has favored CVS with multiple price target increases in recent weeks, though ELV maintains a more stable valuation profile.
- Relative momentum favors CVS in the near term amid healthcare sector rotation and product expansions such as GLP-1 weight-loss treatments.
Introduction
CVS Health (CVS) and Elevance Health (ELV) represent two prominent players in the U.S. healthcare services industry, offering investors exposure to pharmacy operations, insurance, and managed care. This comparison examines their business models, recent financial results, and stock performance to assist portfolio managers, institutional investors, and individual traders evaluating relative positioning within the healthcare sector. The analysis draws on verifiable market data and company disclosures to highlight contrasts in growth trajectories, operational focus, and market sentiment over recent weeks.
CVS Overview and Recent Performance
CVS Health operates an integrated healthcare model encompassing retail pharmacies, pharmacy benefit management through CVS Caremark, and insurance via Aetna. In its first quarter of 2026, the company posted total revenues of $100.4 billion, up 6.2% year-over-year, alongside adjusted earnings per share of $2.57. Management raised full-year 2026 guidance, citing revenue expansion and operational efficiencies. The stock has shown positive momentum in recent market activity, with gains of about 7.5% over the past month and year-to-date returns near 34%. Sentiment has been supported by expansions in weight-loss drug offerings and multiple analyst price target upgrades.
ELV Overview and Recent Performance
Elevance Health provides managed care services, including Medicare Advantage, Medicaid, and commercial plans. For the first quarter of 2026, operating revenue reached $49.5 billion, a 1.5% increase from the prior year, with adjusted diluted earnings per share of $12.58. The company raised its full-year 2026 adjusted earnings guidance to at least $26.75. Stock performance has been steadier, with year-to-date returns around 20% and limited movement in the most recent month. Market positioning reflects focus on government programs and cost-management initiatives ahead of second-quarter results scheduled for mid-July 2026.
Trending AI Robots
Tickeron maintains a curated Trending AI Robots section that highlights top-performing AI trading bots from a library of hundreds available across thousands of tickers. Only those demonstrating the strongest alignment with prevailing market conditions, consistent backtested metrics, and favorable risk-reward profiles are featured. Available bots span diverse trading styles, strategies, timeframes, and performance statistics, including varying win rates and drawdown profiles. This selection process allows traders to identify suitable automated approaches for specific market environments. Review the Trending AI Robots page for current options.
Head-to-Head Comparison
CVS Health employs a diversified business model spanning retail, pharmacy benefit management, and insurance, providing multiple revenue streams that can buffer sector-specific pressures. Elevance Health concentrates on managed care and government-sponsored programs, offering exposure primarily to enrollment trends and medical cost ratios. Recent momentum has favored CVS, evidenced by stronger quarterly revenue growth and outperformance in year-to-date returns. Risk factors differ: CVS faces retail pharmacy margin pressures and regulatory scrutiny around reimbursement, while ELV contends with Medicaid rate dynamics and medical loss ratio variability. Sector exposure for both remains healthcare-centric, though CVS offers incremental retail and pharmacy benefit management tilt. Market sentiment, as reflected in recent analyst actions, appears more constructive toward CVS amid product expansions.
Tickeron AI Verdict
Based on observable factors including stronger recent trend consistency, revenue growth differentials, and positioning ahead of sector catalysts, Tickeron’s AI models currently assign a higher probability of near-term outperformance to CVS relative to ELV. ELV demonstrates greater stability in certain valuation metrics, but CVS exhibits more pronounced momentum signals in recent market activity.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CVS is a Buy and ELV is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CVS’s FA Score shows that 3 FA rating(s) are green whileELV’s FA Score has 3 green FA rating(s).
- CVS’s FA Score: 3 green, 2 red.
- ELV’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CVS’s TA Score shows that 3 TA indicator(s) are bullish while ELV’s TA Score has 4 bullish TA indicator(s).
- CVS’s TA Score: 3 bullish, 5 bearish.
- ELV’s TA Score: 4 bullish, 4 bearish.
Price Growth
CVS (@Managed Health Care) experienced а +3.74% price change this week, while ELV (@Managed Health Care) price change was +4.16% for the same time period.
The average weekly price growth across all stocks in the @Managed Health Care industry was +0.83%. For the same industry, the average monthly price growth was +7.45%, and the average quarterly price growth was +35.30%.
Reported Earning Dates
CVS is expected to report earnings on Aug 05, 2026.
ELV is expected to report earnings on Jul 15, 2026.
Industries' Descriptions
@Managed Health Care (+0.83% weekly)Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.
| CVS | ELV | CVS / ELV | |
| Capitalization | 135B | 92.3B | 146% |
| EBITDA | 11.1B | N/A | - |
| Gain YTD | 35.721 | 22.531 | 159% |
| P/E Ratio | 46.45 | 18.02 | 258% |
| Revenue | 408B | 200B | 204% |
| Total Cash | 11.8B | N/A | - |
| Total Debt | 78.3B | 31.8B | 246% |
CVS | ELV | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 4 Undervalued | 7 Undervalued | |
PROFIT vs RISK RATING 1..100 | 66 | 84 | |
SMR RATING 1..100 | 88 | 98 | |
PRICE GROWTH RATING 1..100 | 7 | 18 | |
P/E GROWTH RATING 1..100 | 5 | 26 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CVS's Valuation (4) in the Drugstore Chains industry is in the same range as ELV (7) in the Managed Health Care industry. This means that CVS’s stock grew similarly to ELV’s over the last 12 months.
CVS's Profit vs Risk Rating (66) in the Drugstore Chains industry is in the same range as ELV (84) in the Managed Health Care industry. This means that CVS’s stock grew similarly to ELV’s over the last 12 months.
CVS's SMR Rating (88) in the Drugstore Chains industry is in the same range as ELV (98) in the Managed Health Care industry. This means that CVS’s stock grew similarly to ELV’s over the last 12 months.
CVS's Price Growth Rating (7) in the Drugstore Chains industry is in the same range as ELV (18) in the Managed Health Care industry. This means that CVS’s stock grew similarly to ELV’s over the last 12 months.
CVS's P/E Growth Rating (5) in the Drugstore Chains industry is in the same range as ELV (26) in the Managed Health Care industry. This means that CVS’s stock grew similarly to ELV’s over the last 12 months.
| CVS | ELV | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 65% | 4 days ago 67% |
| Stochastic ODDS (%) | 4 days ago 60% | 4 days ago 53% |
| Momentum ODDS (%) | 4 days ago 58% | 4 days ago 65% |
| MACD ODDS (%) | 4 days ago 68% | 4 days ago 65% |
| TrendWeek ODDS (%) | 4 days ago 59% | 4 days ago 58% |
| TrendMonth ODDS (%) | 4 days ago 60% | 4 days ago 56% |
| Advances ODDS (%) | 6 days ago 67% | 12 days ago 56% |
| Declines ODDS (%) | 8 days ago 58% | 14 days ago 56% |
| BollingerBands ODDS (%) | 4 days ago 76% | 4 days ago 64% |
| Aroon ODDS (%) | 4 days ago 66% | 4 days ago 56% |
Advertisement
ELV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ELV has been loosely correlated with UNH. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if ELV jumps, then UNH could also see price increases.